Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
115 hedge funds and large institutions have $519M invested in Poseida Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 26 closing their positions.
239% more capital invested
Capital invested by funds: $153M → $519M (+$366M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
20% more funds holding
Funds holding: 96 → 115 (+19)
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
67% less call options, than puts
Call options by funds: $1.45M | Put options by funds: $4.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$26.7M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$13.8M |
| 3 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$10.5M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$3.58M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.8M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$14M |
| 3 |
Millennium Management
New York
|
-$10.7M |
| 4 |
Renaissance Technologies
New York
|
-$3.27M |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$3.18M |
PSTX Hedge Fund Activity: Q4 2024 in Review
115 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2024, worth a combined $519M — up 239% from $153M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PSTX positions and 26 closed out — a net gain of 19 holders — while 31 added to existing stakes and 27 trimmed.
The largest buyer was Nomura Holdings, opening a new position worth an estimated $26.7M. The largest seller was Fidelity Investments, cutting an estimated $23.8M.
- 115 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2024, up from 96 in Q3 2024.
- Funds reported $519M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2024, up 239% quarter-over-quarter.
- 45 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2024 and 26 closed out, a net change of +19 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2024 was Nomura Holdings, an estimated $26.7M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2024 was Fidelity Investments, an estimated $23.8M sold.
Based on aggregated 13F filings for Q4 2024.